Solute carrier family 6 member 14 (SLC6A14): Expression, function, regulation, and impact on tumor progression
Biochemical Pharmacology · 2026-09 · 251 · 118182
DOI: 10.1016/j.bcp.2026.118182 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2026-09. Verfasst von Wenchong Zang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, China; Center for Clinical Pharmacy, Can…. Hauptthemen laut MEDLINE: Disease Progression, Neoplasms, Gene Expression Regulation, Neoplastic, Amino Acid Transport Systems. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 135 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents.
Abstract (Originalsprache)
Solute carrier family 6 member 14 (SLC6A14/ATB0,+) is a broad-spectrum, Na+/Cl--dependent amino acid transporter. It mediates the active uptake of nearly all essential amino acids and serves as a critical metabolic hub under physiological and pathological conditions. To fully understand its potential as a therapeutic target for cancer intervention, this review systematically elucidates the structural biology, regulatory networks, and multifaceted roles of SLC6A14 in cancer. By examining the expression patterns of SLC6A14 in physiological and pathological situation, we demonstrate that it's significantly upregulated in various "amino acid-dependent" malignancies. It includes pancreatic cancer, colorectal cancer, and estrogen receptor-positive breast cancer, where it drives multiple signaling pathways and promotes tumor progression through diverse mechanisms. Beyond its classical metabolic functions, SLC6A14-mediated nutrient deprivation establishes a "nutrient-based immune evasion" mechanism, elucidating its potential for intervention in tumor immunity. Furthermore, we outline a dual-pronged therapeutic strategy for SLC6A14, including its use as a target for pharmacological inhibition and as a delivery channel for amino acid-conjugated prodrugs. Finally, we emphasize that successful clinical translation requires a shift from biomarker-driven patient stratification to mechanism-driven implementation. This highlights the central role of SLC6A14 as an intervenable target at the intersection of cancer metabolism, immune regulation, and targeted therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, China; Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospi…
- Department of Pharmacy, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, China.
- Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, China.
- Department of Pharmacology, College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, China.
- Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, China; Zhejiang Provincial Clinical Research…
Förderung
- National Natural Science Foundation of China
- Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents
Zitieren
APA
Zang, W., Zhang, Z., Zhi, Y., Zhang, W., Song, F., & Huang, P. (2026). Solute carrier family 6 member 14 (SLC6A14): Expression, function, regulation, and impact on tumor progression. Biochemical Pharmacology, 251, 118182. https://doi.org/10.1016/j.bcp.2026.118182
Vancouver
Zang W, Zhang Z, Zhi Y, Zhang W, Song F, Huang P. Solute carrier family 6 member 14 (SLC6A14): Expression, function, regulation, and impact on tumor progression. Biochemical Pharmacology. 2026;251:118182. doi:10.1016/j.bcp.2026.118182
BibTeX
@article{Zang2026,
author = {Zang, Wenchong and Zhang, Zhentao and Zhi, Ye and Zhang, Wen and Song, Feifeng and Huang, Ping},
title = {Solute carrier family 6 member 14 (SLC6A14): Expression, function, regulation, and impact on tumor progression},
journal = {Biochemical Pharmacology},
year = {2026},
volume = {251},
pages = {118182},
doi = {10.1016/j.bcp.2026.118182}
}
EUVIMED